SCHEMBL6839397

SCHEMBL6839397

CC(C)(C)[Si](C)(C)O[C@H](C=CI)Cc1cccc2ccccc12

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CTNNB1 P35222 1/20 0.38
CTSS P25774 1/20 0.36
CTSK P43235 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
CYP1A2 P05177 2/20 0.35
CYP2C19 P33261 2/20 0.35
CYP2D6 P10635 1/20 0.35
TACR1 P25103 2/20 0.34
TDP1 Q9NUW8 1/20 0.34
SIGMAR1 Q99720 1/20 0.34
MMP9 P14780 1/20 0.34
ATM Q13315 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
GAA P10253 1/20 0.33
HPGD P15428 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CYP2C9 P11712 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6839393 1.00 CTNNB1 (0.38) CTNNB1CTSSCTSKL3MBTL1CYP1A2
SCHEMBL967565 0.81 CYP2A6 (0.40) CTSSCTSKCYP2D6TACR1MMP9
SCHEMBL967564 0.81 CYP2A6 (0.40) CTSSCTSKCYP2D6TACR1MMP9
SCHEMBL4504374 0.80 TAAR1 (0.33) CYP1A2TDP1SIGMAR1ALDH1A1
SCHEMBL4504372 0.80 TAAR1 (0.33) CYP1A2TDP1SIGMAR1ALDH1A1
SCHEMBL6650896 0.80 TAAR1 (0.33) CYP1A2TDP1SIGMAR1ALDH1A1
SCHEMBL6650902 0.80 TAAR1 (0.33) CYP1A2TDP1SIGMAR1ALDH1A1
SCHEMBL970714 0.79 HTR2A (0.41) CTSSCTSKCYP1A2TACR1SIGMAR1
SCHEMBL660879 0.77 AGXT (0.42)
SCHEMBL6844414 0.77 AGXT (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6767920-B2 ADMINISTERING TO AN ANIMAL HAVING OCULAR HYPERTENSION OR GLAUCOMA THERAPEUTICALLY EFFECTIVE AMOUNT OF 3 OR 7 OR 3 AND 7 THIA-PROSTANOIC ACID, ESTER, AMIDE, PHOSPHONATE OR OTHER DERIVATIVES ALLERGAN, INC. 2004-07-27 US disclosed
US-20030144254-A1 3, 7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure ALLERGAN SALES, INC. 2003-07-31 US disclosed
US-20030027853-A1 Potent ocular hypotensives that are particularly suited for the management of glaucoma. ALLERGAN SALES, INC. 2003-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030027853-A1 Potent ocular hypotensives that are particularly suited for the management of glaucoma. CBR3, SCO2, CBR1 CTNNB1 993/4885CTSS 2952/4885CTSK 4015/4885
US-20030144254-A1 3, 7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure PTGIR, OXER1, CBR1 CTNNB1 764/4885CTSS 4532/4885CTSK 4802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.